HIMS to offer Liraglutide after shortage rule changes

HIMS leans into Liraglutide as a replacement for Semaglutide in the face of shortage rule changes. Is it good enough?

Adlyxin's 2025 Patent expiry

Aldyxin' approaching 2025 patent expiry and what it could mean for new GLP1 drugs.

Research models applied to GLP1s and Plateaus

New research that shows a benefit to appetite feedback control circuits via mathematical modeling, showing the benefits of using GLP1s.

22.7% weight loss yet Novo Nordisk stock drops 27%

Novo Nordisk's new CagriSema drug showed weight loss results that are *stunning*, but less than what Wall Street expected.

Semaglutide & Liraglutide continue to be effective

Semaglutide and Liraglutide continue to be researched and studied and produce positive results for weight loss and medical outcomes.

Lizzo's as a lens on GLP1 public opinion

We view the the reflection of public opinion on GLP1s and drugs like Ozempic, Mounjaro, and Zepbound through an unusual lens: Lizzo.

Eli Lilly brands GLP1s as "anti-hedonics"

Eli Lilly leans into the use of GLP1s for reducing addictive behavior, labeling them "anti-hedonics"

How much are people paying for GLP1s? (2024/11)

We take another look at reports of what people are paying for GLP1s with/without insurance and everywhere in between.

A list of FDA approved GLP1s

A list of FDA approved GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, etc), for easy reference.

Anxiety and suicidal thoughts after stopping GLP1s?

Reports of anxiety and suicidal reports have been reported for people after *stopping* use of GLP1s. We dig in, and weight the FDA's comments.

Biden-Harris administration keen on GLP1s

The outgoing Biden-Harris admin puts out a proposal on widening access to GLP1s, which we hope the incoming Trump admin will also adopt.

Weight loss "stalling" on GLP1s?

What happens when weight loss stalls on GLP1s? We check around the GLP1 community to see what people have figured out.